OrBIT Study Long Term Results Show Sustained Therapeutic ffect Of Percutaneous Tibial Nerve Stimulation At 12 onths

Uroplasty, Inc NYS Amex: UPI, a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding dysfunctions, highlighted the 12-month results of the OrBIT Trial of its Urgent® P Neuromodulation System that will be published in the January 2010 print edition of TH JOURNAL OF UROLOGY® The Urgent P System is a proprietary, minimally invasive, percutaneous tibial nerve stimulation PTNS device designed for office-based treatment of urinary urgency, urinary frequency and urge incontinence, symptoms often associated with overactive bladder OAB

The long-term phase of the OrBIT Trial reported on 25 patients who had significant symptom improvement in the initial 12-week phase of the OrBIT Trial and continued PTNS therapy at increasing time intervals between treatments over a 12-month period

Highlights from the study include:

— 96% of PTNS patients considered their urinary symptoms cured or improved at 12 months

— Investigators also considered 96% of PTNS patients cured or improved at 12 months

— At 12 months statistically significant changes compared to baseline included:

— Decrease in voiding episodes by 28 voidsday

— Decrease in urge incontinence episodes by 16day

— Decrease in nighttime voids by 08night

— Increase in voided volume of 39 cc

— PTNS patients also reported significant quality of life improvements

— No serious adverse events were reported

— From the 12-week visit through the 12-month visit, average interval between treatments was 21 days

“The durability of response demonstrates the effectiveness of percutaneous tibial nerve stimulation and strongly supports PTNS as a viable, long-term therapy for overactive bladder” said Dr Scott acDiarmid, the primary author, and Director of the Bladder ontrol and Pelvic Pain enter at Alliance Urology Specialists, Greensboro, N “PTNS represents an important addition to our therapeutic armamentarium This study data is very exciting because the results mirror what we have observed in our clinical practice over the last three years”

Publication of the 12-month results follows that of the 12-week OrBIT Overactive Bladder Innovative Therapy multi-center trial in TH JOURNAL OF UROLOGY, September, 2009 The 12-week results demonstrated that patients treated with PTNS had clinical improvement comparable to patients treated with an oral extended release OAB drug with fewer significant side effects

“These results confirm that PTNS sustains the therapeutic effect that patients experienced during the initial 12-week study,” said Dave Kaysen, President and hief xecutive Officer of Uroplasty, Inc “The investigators’ assessments mirrored that of the patients which demonstrates both objective and subjective measures improved Urgent P is an effective and viable option for treating urinary symptoms often associated with overactive bladder We will use these results to continue to educate medical directors about PTNS effectiveness to establish reimbursement This study is also part of the clinical data that has been presented to the American edical Association as part of our application for a unique PT code for PTNS” added r Kaysen

About the Urgent P Neuromodulation System

The Urgent P neuromodulation system is a proprietary, minimally invasive nerve stimulation device designed for office-based treatment of urge incontinence, urinary urgency and urinary frequency, symptoms often associated with overactive bladder Application of neuromodulation therapy targets specific nerve tissue and disrupts the signals that lead to these symptoms Uroplasty sells the Urgent P system in the United States, anada, and countries recognizing the mark Outside of the United States, Urgent P is also indicated for the treatment of fecal incontinence

About Uroplasty, Inc

Uroplasty, Inc, headquartered in innetonka, innesota, with wholly-owned subsidiaries in The Netherlands and the United Kingdom, is a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions Our focus is the continued commercialization of our Urgent P system, which we believe is the only FDA-approved minimally invasive nerve stimulation device designed for office-based treatment of urinary urgency, urinary frequency and urge incontinence, symptoms often associated with overactive bladder

We also offer acroplastique® Implants, an injectable urethral bulking agent for the treatment of adult female stress urinary incontinence primarily due to intrinsic sphincter deficiency

Forward-Looking Information

This press release contains forward-looking statements, which reflect our best estimates regarding future events and financial performance These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from our anticipated results We discuss in detail the factors that may affect the achievement of our forward-looking statements in our Annual Report on Form 10-K filed with the S Further, we cannot assure you that we will timely obtain, or even succeed at all at obtaining, a unique PT reimbursement code from the American edical Association for Urgent P treatments, that even if we obtain a unique PT reimbursement code third-party payors will provide or continue to provide coverage and reimbursement, or reimburse the providers an amount sufficient to cover their costs and expenses

Source: Uroplasty, Inc

source : www.medicalnewstoday.com

Related News:

• Hutterite study: Vaccinating kids for flu may help prevent transmission, protect those who are not vaccinated
• Researchers Develop Tool To Help Study Prostate Cancer
• Hospice Study Finds Racial Disparities (CME/CE)
• Shoulder Function Not Fully Restored After Surgery: Henry Ford Hospital Study
• Hospice Study Finds Racial Disparities
• Phase III REGION-I Study Shows PEP005 (ingenol Mebutate) Gel 0.05% May Reduce Pre-Cancerous Skin Lesions In Patients With Actinic Keratosis
• Prolonged Use Of HRT Increases Incidence Of Lung Cancer By About 50 Percent: New Study
• pSivida Reports Presentation Of Additional Positive 24-Month Data From Iluvien(R) Phase 3 FAME™ Study For Diabetic Macular Edema At Angiogenesis
• Second Dose Of Gene Therapy For Inherited Blindness Proves Safe In Animal Study
• Study Supports Conventional CPR for Children in Arrest